Current Studies
Primary: to assess the efficacy of cryoablation therapy in the treatment of esophageal adenocarcinoma as adjuvant, neoadjuvant or palliative therapy.
Secondary: to assess the safety of cryoablation therapy in the treatment of esophageal cancer
View Details
Current Studies
Primary Objectives
- Objective: To compare the HIF triplet to the
doublet with respect to PFS per RECIST 1.1
as assessed by BICR.
- Hypothesis (H1): The HIF triplet is superior
to the doublet with respect to PFS per
RECIST 1.1 by BICR in advanced ccRCC
patients with IMDC intermediate/poor risk.
-...
View Details
Current Studies
Feasibility Research Objectives
For the purposes of the pilot phase, the primary objective will be to determine whether it is feasible to conduct a large multi-center RCT that will evaluate the impact of surveillance strategies on patient survival following extremity STS surgery. To do so, we will...
View Details
Current Studies
Primary Objective:
To evaluate the safety and tolerability of RBX2660 in subjects with recurrent CDI.
Secondary Objectives:
1. To evaluate the efficacy of RBX2660 in preventing recurrent episodes of CDI through 8 weeks after treatment.
2. To evaluate the sustained clinical response rate of...
View Details
Current Studies
Primary Outcome Measures
Incidence of adverse events following administration of BBP-671 (Time Frame= 43 day)
BBP-671 concentration dependent change in change from baseline in QTcF (Time Frame= 43 days)
Pharmacokinetic Assessments: Cmax (Time Frame= 43 days)
Time to maximum concentration...
View Details
Current Studies
OBJECTIVES:
Develop Integrated Biomedical Computing Tools (IBCT) for the better understanding and treatment of pancreatic cancer by using the power of computer and informatics sciences.
Continue development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure to act as a...
View Details
Current Studies
Primary Objectives:
To centrally test resected NSCLC for genetic mutations to facilitate accrual to randomized adjuvant studies.
To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to...
View Details
Current Studies
This study will determine recurrence and complication rates for those that have undergone endoscopic mucosal resection of colorectal polyps at Parkview Regional Medical Center.
View Details
Current Studies
Primary Aim 1. Determine the association of GEP test result with SLNB surgical decisions in patients with SLNB-eligible T1-T2 melanoma
Primary Aim 2: Track and evaluate 5-year clinical outcomes for patients in each GEP subclass, including those who did and did not undergo SLNB and those with T3-T4...
View Details
Current Studies
The purpose of this study is to assess correlations between expression of blood serum biomarkers and cognitive impairment (CI) in patients with colorectal cancer throughout and following chemotherapy treatment. Our primary goal is to establish a panel of biomarkers that predict CI that can be...
View Details
Current Studies
Determine if early treatment with dronedarone is superior to usual care for the prevention of cardiovascular hospitalization or death from any cause in patients with first-detected atrial fibrillation.
View Details
Current Studies
The main endpoint is the technical success rate of EFTR of UGIT lesions using gFTRD including
A. Technical success
B. Histological margin
Secondary end points include:
A. Adverse events
B. Procedure time
C. Residual or recurrence of lesion on repeat endoscopy
View Details
Current Studies
- Objective: To compare pathologic complete
response (pCR) rates obtained in Arm A
(preoperative pembrolizumab and
RC+PLND) and Arm B (RC+PLND), based
on central pathologic review, evaluated in
participants whose tumors express PD-L1
CPS ≥10 and all participants, irrespective of
CPS score.
-...
View Details
Current Studies
Primary Objective:
To determine the effect of cryoablation combined with chemotherapy on the quality of life (QOL) of patients with non-resectable esophageal or gastroesophageal cancer.
Secondary Objective:
To determine the effect of cryotherapy on dysphagia scores
To describe the safety profile...
View Details
Current Studies
Primary Endpoint: To identify a gene expression and/or mutational profile that can separate primary cSCC tumors that have a high risk of recurrence compared to primary cSCC tumors that have a low risk of recurrence using RT-PCR and RNA sequencing (RNASeq).
Secondary Endpoint: To validate the...
View Details
Current Studies
Primary Objective
To compare the rate of molecular response 4.5 (MR4.5) after 12 months of combination therapy with ruxolitinib plus a TKI (dasatinib or nilotinib) versus a TKI alone, based on local PCR testing to measure BCR-ABL transcripts in chronic phase CML patients with molecular evidence of...
View Details
Current Studies
Primary Outcome Measures:
Accuracy of PCL diagnosis [Time Frame: 48 months]
Diagnostic accuracy of confocal laser endomicroscopy and/or cyst fluid molecular markers and/or composite clinical and imaging features for the diagnosis of mucinous PCLs, PCLs with malignant potential, specific PCL types,...
View Details
Current Studies
To identify the incidence of and variables associate with those patients found to have pancreatic tumors upon Endoscopic Ultrasound that were unidentifiable on CT/MRI imaging.
View Details
Current Studies
Primary:
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [Time Frame: Up to approximately 38 months]
Overall Survival (OS) [Time Frame: Up to approximately 46 months]
Secondary:
Progression-Free Survival (PFS) Per Response Evaluation...
View Details
Current Studies
The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of PSVT in an outpatient setting.
Primary Outcome Measures:
1. The time to conversion of an episode of PSVT to sinus rhythm (SR) after study drug...
View Details
Current Studies
Co-primary Objectives
To determine the progression free survival (PFS) for paclitaxel with and without nivolumab in subjects with taxane na�ve angiosarcoma.
To determine the overall response rate (ORR) of nivolumab in combination with cabozantinib in patients with taxane pre-treated...
View Details
Current Studies
Central Hypothesis: Histological and endoscopic features of the papilla impact recurrence. Recurrence is higher in patients with Familial adenomatous polyposis than with sporadic adenomas of the papilla.
Specific Aim #1:
Rate of recurrence of ampullary adenomas in patients with and without...
View Details
Current Studies
Primary Objective:
To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine,...
View Details
Current Studies
Primary Objectives
Phase II
To assess the efficacy of concurrent definitive therapy followed by nivolumab compared with concurrent definitive therapy followed by observation in terms of progression-free survival (PFS).
Phase III
To assess the efficacy of concurrent definitive therapy followed by...
View Details
Current Studies
To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator
Hypothesis (H1): pembrolizumab plus paclitaxel with or without bevacizumab is...
View Details
Current Studies
Primary Outcome Measures :
Objective Response Rate (ORR) [ Time Frame: 24 months ]
ORR will be measured from the date of enrollment to date of progression (in months) based on RECIST 1.1 criteria. The analysis will include patients with PD-L1 expression TPS≥1-49 percent and TPS≥50...
View Details
Current Studies
Primary:
Create a large scale, population-based registry of full genome expression data matched with clinical data to investigate new gene associations with prognostic and/or predictive value
Utilize registry data to graduate identified expression signatures into subset trials and recommend...
View Details
Current Studies
Primary Outcome Measures:
*Safety of patient management pathway - Proportion of medication interventions with associated medication intervention related serious adverse events (Time Frame: Up to 3 years)
*The proportion of medication interventions with one or more associated medication...
View Details
Current Studies
It is the aim of this study to analyze the outcomes of endoscopic esophageal stent placement in those with esophageal cancer
View Details
Current Studies
Primary:
1. The primary objective is to evaluate the safety of self-administered
etripamil nasal spray (NS) outside of the clinical setting.
Secondary Objectives:
1. To evaluate the efficacy of self-administered etripamil NS outside
of the clinical setting, and
2. To evaluate the impact of...
View Details
Current Studies
To compare the progression-free survival (PFS) of treatment with dostarlimab plus carboplatin-paclitaxel to treatment with placebo plus carboplatin-paclitaxel, as assessed by the Investigator per RECIST v.1.1, in the following: [ Time Frame: Up to 5 years ]
* All subjects with recurrent or...
View Details
Current Studies
Primary Objective:
-To compare MK-
6482+lenvatinib to cabozantinib with
respect to PFS per Response Criteria in
Solid Tumors (RECIST) 1.1 as assessed
by blinded independent central review
(BICR).
-Hypothesis (H1): MK-6482+lenvatinib is
superior to cabozantinib with respect to
PFS per RECIST 1.1 by...
View Details
Current Studies
Primary
To compare disease-free survival (DFS) as assessed by investigator for participants treated with belzutifan plus pembrolizumab versus those receiving placebo plus pembrolizumab
Hypothesis (1): Belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to...
View Details
Current Studies
Primary Objective
To assess whether adjuvant therapy with erlotinib will result in improved overall survival (OS) over observation for patients with completely resected stage IB (4 cm)-IIIA EGFR mutant NSCLC (confirmed centrally) following complete resection and standard post-operative...
View Details
Current Studies
Objectives
1. To compare efficacy of EMR to Laparoscopic Colon Resection (hemicolectomy) in the treatment of benign, flat colon polyps
2. To compare safety of EMR to Laparoscopic Colon Resection (hemicolectomy) in the treatment of benign, flat colon polyps
3. To compare cost...
View Details
Current Studies
The primary objective of this study is to evaluate the safety and tolerability of NanoPac injected into lung cancer lesions by EBUS-TBNI on multiple (up to three) occasions, each injection procedure administered 4 weeks apart. Safety and tolerability will be assessed for 24 weeks following first...
View Details
Current Studies
PRIMARY OBJECTIVE
To assess the effect of in-hospital initiation of
dapagliflozin, as compared with placebo, on
the clinical outcomes of cardiovascular death
or worsening heart failure in patients who have been stabilized during
hospitalization for acute heart failure.
To evaluate the safety and...
View Details
Current Studies
It is the aim of this study to analyze the outcomes of esophageal perforation with esophageal fully covered metal stents or endoscopic suturing.
View Details
Current Studies
PRIMARY OBJECTIVES:
I. To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical...
View Details
Current Studies
Primary Objective
To evaluate the response rate (confirmed, complete or partial) of AMG 510 in participants with KRASG12C mutated Stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC). The response rates will be evaluated separately with cohorts defined as:
i. Cohort 1 (co-mutation...
View Details
Current Studies
Primary:
To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab plus olaparib to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival per RECIST 1.1 as assessed by blinded independent central review.
To compare...
View Details
Current Studies
Specific Study Aims:
Study Aim 1: The primary aim of this study was to determine the technical success of ESD using the retraction device by determining completeness of the resection (�en-bloc vs incomplete).
Study Aim 2: We aim to determine the safety of the device with regards to perforation and...
View Details
Current Studies
Primary Objective
a To evaluate the RECIST v1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
b To evaluate the overall response rate (ORR, per criteria in Section 10.8) in patients with gestational...
View Details
Current Studies
Primary Objective: To determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the...
View Details
Current Studies
Primary Objective
Non-inferiority of partial breast irradation (PBI) and concurrent compared to sequential chemotherapy with respect to acute grade 3-4 radiation toxicity
Secondary Objectives
Evaluate and compare any first tumor recurrence (local plus distant) between arms of the study.
Evaluate...
View Details
Current Studies
Primary
An Excision of the targeted lesion in a single specimen
Secondary
Rate of R0 resection Time Frame 3-4 hours
when all vertical and horizontal margins are negative
Rate of R1 resection Time Frame 3-4 hours
complete resection with no grossly visible lesion defined by...
View Details
Current Studies
Central Hypothesis: Endoscopic submucosal dissection with and without adjuvant therapy (XRT, chemotherapy based on final precise pathology) allows for adequate management of T1b N0 EAC and SCC.
Specific Aim #1: To assess the long-term outcomes (local and metastatic recurrence) of ESD +/- adjuvant...
View Details
Current Studies
Primary:
Progression-free survival (PFS)
To determine the efficacy by progression free survival
(using investigator assessment of scans according to
RECIST v1.1) of oregovomab compared to placebo
when administered with background chemotherapy
(paclitaxel/carboplatin) to subjects with...
View Details
Current Studies
Primary Objective:
To evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) for patients with stage IB greater than or equal to 4cm, II and IIIA, ALK-positive NSCLC following surgical resection.
Secondary Objectives:
To evaluate and compare disease-free...
View Details
Current Studies
The HPS-4/TIMI 65/ORION-4 study aims to provide evidence about both the efficacy and safety of inclisiran. Consistent with relevant guideline recommendations for people with vascular disease, it is intended that participants be on intensive background LDL-lowering therapy, at screening. The...
View Details
Current Studies
Primary Objective
To compare the efficacy of single-agent olaparib and the combination of olaparib and cediranib (and potentially other combination arms that may be added by subsequent amendment) versus single agent cediranib as measured by progression free survival (PFS), in patients with...
View Details
Current Studies
Primary:
* To identify risk factors in patient history among patients evaluated at the Fall Prevention Clinic.
Secondary:
* To compare the characteristics of adult patients who experience falls v/s those who do not.
* To review findings on examination (general and neurological) and testing...
View Details
Current Studies
Primary Objective of the Master Protocol (LungMAP)
The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Secondary Objectives
a....
View Details
Current Studies
Primary Objective
To examine if letrozole monotherapy/maintenance is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction.
Secondary...
View Details
Current Studies
Primary Outcome Measures :
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment [ Time Frame: Up to end of treatment (average 3 years) ]
ORR, is defined as the rate of the overall best response, complete response (CR) or...
View Details